The U.S. Food and Drug Administration gave Emergency Use Authorization (EUA) to a Covid-19 test developed by Roche that measures antibodies within the blood.
The Takeda Pharmaceutical Co.-led group that is developing a blood plasma treatment for Covid-19 started manufacturing while the late-stage trial to determine whether the hyperimmune globulin therapy works is ongoing, Chief Executive Christophe Weber said.
Japan’s Takeda Pharmaceutical said on Friday an alliance of drugmakers the company spearheads enrolled the first patient in a global clinical trial of a blood plasma treatment for Covid-19 after months of regulatory delays.
The CoVIg-19 Plasma Alliance was founded to accelerate development of a plasma-derived hyperimmune globulin therapy against COVID-19.
